Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Steven D. Targum"'
Autor:
Christian Yavorsky, Elizabeth Ballard, Mark Opler, Jan Sedway, Steven D. Targum, William Lenderking
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can generate responses within hours or days, rather than weeks or months. Thes
Externí odkaz:
https://doaj.org/article/b0048f13eb43427aba89945beb0ca7ae
Publikováno v:
Contemporary Clinical Trials Communications, Vol 14, Iss , Pp - (2019)
Ratings surveillance is used in clinical trials to assure ratings reliability of site-based scores. One surveillance method employs audio-digital recordings of site-based clinician interviews to obtain remote, site-independent scores for assessment o
Externí odkaz:
https://doaj.org/article/7dfddbe4e8fa41548bad59622c424669
Autor:
Steven D. Targum, Jeffrey Schappi, Athanasia Koutsouris, Runa Bhaumik, Mark H. Rapaport, Natalie Rasgon, Mark M. Rasenick
Publikováno v:
Molecular Psychiatry. 27:1640-1646
Publikováno v:
Journal of Psychiatric Research. 144:241-246
Blinded, site-independent (remote) ratings from audio-digital recordings of site-based Positive and Negative Syndrome Scale (PANSS) interviews were obtained in a 5-week, randomized, double-blinded study assessing the safety, tolerability, and efficac
Autor:
Anna D. Burke, Kristen E. Drake, Lisa Fosdick, Steven D. Targum, Gwenn S. Smith, Constantine G. Lyketsos, Marwan N. Sabbagh, Paul B. Rosenberg, Wael F. Asaad, Kelly D. Foote, Andres M. Lozano, David A. Wolk
Publikováno v:
Journal of Alzheimer's Disease
Background: Age may affect treatment outcome in trials of mild probable Alzheimer’s disease (AD). Objective: We examined age as a moderator of outcome in an exploratory study of deep brain stimulation targeting the fornix (DBS-f) region in particip
Publikováno v:
Journal of Psychiatric Research. 136:256-264
We used ecological momentary assessment (EMA) to track symptoms during a clinical trial. Thirty-six participants with major depressive disorder (MDD) and MADRS scores ≥20 were enrolled in a nonrandomized 6-week open-label trial of commercially avai
Autor:
Steven D. Targum
Publikováno v:
JAMA psychiatry. 79(4)
Publikováno v:
Journal of Psychiatric Research. 121:118-125
Early score fluctuation in double-blind, placebo-controlled studies may affect the reliability of the baseline measurement and adversely affect the eventual study outcome. We examined the effect of early score fluctuation during a 2-week double-blind
Autor:
Steven D, Targum, Jeffrey, Schappi, Athanasia, Koutsouris, Runa, Bhaumik, Mark H, Rapaport, Natalie, Rasgon, Mark M, Rasenick
Publikováno v:
Molecular psychiatry. 27(3)
In contrast to healthy controls, the heterotrimeric G protein, Gsalpha (Gsα) is ensconced predominantly in lipid rafts in subjects with major depressive disorder (MDD) resulting in impaired stimulation of adenylyl cyclase. In this small proof-of-con
Publikováno v:
Journal of Psychiatric Research. 107:86-96
We conducted a 6-week double-blind, placebo-controlled, augmentation study comparing the efficacy and safety of MSI-195 800 mg (a proprietary formulation of S-adenosylmethionine) or placebo added to ongoing antidepressant medication (ADT) in acutely